| General Information | |
|---|---|
| ZINC ID | ZINC000095594329 |
| Molecular Weight (Da) | 439 |
| SMILES | CCCCCn1cc(C(=O)NC23CC4C[C@](C)(C2)C[C@@](C)(C4)C3)c(=O)c2c(C)nn(C)c21 |
| Molecular Formula | C26N4O2 |
| Action | Partial Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 126.918 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 32 |
| LogP | 4.232 |
| Activity (Ki) in nM | 9.772 |
| Polar Surface Area (PSA) | 68.92 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | 0 |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.77692711 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 9 |
| Fraction csp3 | 0.73 |
| Ilogp | 4.29 |
| Xlogp3 | 5.48 |
| Wlogp | 4.71 |
| Mlogp | 3.72 |
| Silicos-it log p | 4.85 |
| Consensus log p | 4.61 |
| Esol log s | -5.76 |
| Esol solubility (mg/ml) | 0.000766 |
| Esol solubility (mol/l) | 0.00000175 |
| Esol class | Moderately |
| Ali log s | -6.69 |
| Ali solubility (mg/ml) | 0.0000906 |
| Ali solubility (mol/l) | 0.0000002 |
| Ali class | Poorly sol |
| Silicos-it logsw | -6.74 |
| Silicos-it solubility (mg/ml) | 0.0000794 |
| Silicos-it solubility (mol/l) | 0.00000018 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.08 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 5.87 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.055 |
| Logd | 3.775 |
| Logp | 4.588 |
| F (20%) | 0.003 |
| F (30%) | 0.806 |
| Mdck | 2.10E-05 |
| Ppb | 0.853 |
| Vdss | 2.143 |
| Fu | 0.1682 |
| Cyp1a2-inh | 0.033 |
| Cyp1a2-sub | 0.865 |
| Cyp2c19-inh | 0.268 |
| Cyp2c19-sub | 0.843 |
| Cl | 2.107 |
| T12 | 0.044 |
| H-ht | 0.752 |
| Dili | 0.69 |
| Roa | 0.031 |
| Fdamdd | 0.968 |
| Skinsen | 0.058 |
| Ec | 0.003 |
| Ei | 0.01 |
| Respiratory | 0.22 |
| Bcf | 0.743 |
| Igc50 | 2.873 |
| Lc50 | 2.815 |
| Lc50dm | 5.05 |
| Nr-ar | 0.001 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.64 |
| Nr-aromatase | 0.025 |
| Nr-er | 0.044 |
| Nr-er-lbd | 0.009 |
| Nr-ppar-gamma | 0.013 |
| Sr-are | 0.664 |
| Sr-atad5 | 0.013 |
| Sr-hse | 0.376 |
| Sr-mmp | 0.52 |
| Sr-p53 | 0.846 |
| Vol | 463.855 |
| Dense | 0.945 |
| Flex | 0.292 |
| Nstereo | 4 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 1 |
| Qed | 0.664 |
| Synth | 5.309 |
| Fsp3 | 0.731 |
| Mce-18 | 113.667 |
| Natural product-likeness | -0.963 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Accepted |